Investor News

Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases

Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO). The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates. 

Through its unique platform technology, Confo Therapeutics develops GPCR modulators for patients with severe and underserved diseases, with a specific focus on rare diseases. Among other things, the company intends to address an important target for neurological orphan conditions which is currently considered to be an undruggable GPCR.

The research pursued under the aegis of this VLAIO grant will allow Confo Therapeutics to unlock new potential treatments for unmet disease areas and to simultaneously pursue new technology developments. This should ultimately shorten drug discovery timelines and expand their proprietary pipeline for rare disease indications. ​

Share

Latest stories

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Leuven, 4 November 2026 – Researchers at VIB and KU Leuven have uncovered how mutations in the ASPM gene disrupt the development of neural stem cells that help the human brain grow. This disruption explains how these mutations cause microcephaly, a condition characterized by an abnormally small brain and head, often accompanied by intellectual disability. The discovery, published in Developmental Cell, also sheds light on how differences in brain development can make humans more susceptible to certain genetic conditions than other mammals.

press.vib.be

How blocking immune cell signals could make brain tumors easier to remove

How blocking immune cell signals could make brain tumors easier to remove

Leuven, Belgium, 27 October 2026 – In a new study published in Cancer Cell, researchers at VIB-KU Leuven reduced the spread of glioblastoma by interrupting specific interactions between the brain’s immune cells and tumor cells. The discovery points to a possible new therapeutic strategy, in which blocking communication between immune and cancer cells makes tumors more contained and easier to remove.

press.vib.be

Human stem-cell model reveals a shared origin for tissue-resident macrophages

Human stem-cell model reveals a shared origin for tissue-resident macrophages

VIB researchers have developed a new human stem-cell-based model that recreates an early stage of immune-cell development and shows how a single progenitor population can give rise to specialized macrophages across different organs. The model provides a platform to study how these processes change in disease, and how they might eventually be harnessed therapeutically.

press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be